| OTSUKA PHARMACEUTICAL CO., LTD. Patent applications |
| Patent application number | Title | Published |
|---|
| 20120128857 | CARBONATED DRINK COMPRISING SOYBEAN FLOUR OR SOYBEAN MILK - An object of the present invention is to provide a carbonated beverage containing soybean powder or soymilk, wherein the carbonated beverage is provided with a refreshing carbonic acid flavor as well as nutrients and good flavor derived from soybeans, and the soybean-derived ingredient is stably maintained without becoming coagulated even when the content of the soybean-derived ingredient is high. | 05-24-2012 |
| 20120122245 | ALLOYED METAL COLLOID - Provided is a metal colloid having higher visibility and higher sensitivity than a gold colloid and a Au-core Pt-shell composite colloid and suitable as a labeling agent for use in a test such as an immunoassay. An alloyed Au/Pt composite colloid formed by mixing a gold salt and a platinum salt with at least one reducing agent selected from the group consisting of an amino acid and a derivative thereof, an oligopeptide and a derivative thereof, and an amino sugar in the presence of an alkali, thereby reducing the gold salt and platinum salt. | 05-17-2012 |
| 20120100190 | CONTROLLED RELEASE STERILE INJECTABLE ARIPIPRAZOLE FORMULATION AND METHOD - A controlled release sterile freeze-dried aripiprazole formulation is provided which is formed of aripiprazole of a desired mean particle size and a vehicle therefor, which upon constitution with water and intramuscular injection releases aripiprazole over a period of at least about one week and up to about eight weeks. A method for preparing the controlled release freeze-dried aripiprazole formulation, and a method for treating schizophrenia employing the above formulation are also provided. | 04-26-2012 |
| 20120065162 | N-N-SUBSTITUTED 3-AMINOPYRROLIDINE COMPOUNDS USEFUL AS MONOAMINES REUPTAKE INHIBITORS - The present invention provides a pyrrolidine compound of General Formula (1) | 03-15-2012 |
| 20120064550 | METHOD FOR MEASUREMENT OF EQUOL IN BIOLOGICAL SAMPLE BY IMMUNOASSAY, KIT FOR THE MEASUREMENT, AND METHOD FOR DETERMINATION OF EQUOL PRODUCTION ABILITY OF SUBJECT - An object of the present invention is to provide a method for measuring equol in a biological sample by an immunological method, a kit for the measurement, and a method for determining equol-producing ability of a subject. | 03-15-2012 |
| 20120015025 | CHOLESTANOL DERIVATIVE FOR COMBINED USE - The invention provides a cancer chemotherapeutic agent which has fewer side effects and excellent efficacy. | 01-19-2012 |
| 20120009251 | CHOLESTANOL DERIVATIVE FOR COMBINED USE - The invention provides a cancer chemotherapeutic agent which has fewer side effects and excellent efficacy. The cancer chemotherapeutic agent of the invention includes a cholestanol derivative represented by formula (1): | 01-12-2012 |
| 20120004186 | PLATELET AGGREGATION INHIBITOR COMPOSITION - The invention provides a pharmaceutical composition comprising at least one polypeptide of the following (a) to (d): | 01-05-2012 |
| 20110294143 | METHOD FOR DETECTING ALL HAEMOPHILUS INFLUENZAE - Provided is an immunoassay method whereby all | 12-01-2011 |
| 20110281819 | LOW-MOLECULAR POLYSULFATED HYALURONIC ACID DERIVATIVE AND MEDICINE CONTAINING SAME - A low-molecular-weight polysulfated hyaluronic acid derivative useful for prevention and/or treatment of an allergic disease. An agent for prevention and/or treatment of an allergic disease selected from pollinosis, allergic rhinitis, allergic conjunctivitis, atopic dermatitis, and asthma, represented by the following general formula (IA) or (IB); | 11-17-2011 |
| 20110281284 | NOVEL LIVER CANCER MARKER - According to the present invention, HDGF in the blood of patients with chronic liver disease is measured to diagnose whether the patients have liver cancer. A measurement kit for the diagnosis is also provided. | 11-17-2011 |
| 20110269705 | QUINOLONE COMPOUND AND PHARMACEUTICAL COMPOSITION - The present invention provides a quinolone compound that inhibits the chronic progression of Parkinson's disease or protects dopamine neurons from disease etiology, thereby suppressing the progression of neurological dysfunction, so as to prolong the period of time until L-dopa is administered while also improving neuronal function; the quinolone compound of the invention is represented by Formula (1): | 11-03-2011 |
| 20110251180 | PHARMACEUTICAL AGENT COMPRISING QUINOLONE COMPOUND - The present invention provides a pharmaceutical agent that inhibits the chronic progression of Parkinson's disease or protects dopamine neurons from disease etiology, thereby suppressing the progression of neurological dysfunction, so as to prolong the period of time until L-dopa is administered while also improving neuronal function; the pharmaceutical agent of the invention comprising as an active ingredient a quinolone compound represented by Formula (1): | 10-13-2011 |
| 20110207911 | POLYPEPTIDE DERIVED FROM THE RYANODINE RECEPTOR THAT INHIBITS CALCIUM LEAKAGE - A polypeptide exhibiting the effect of inhibiting Ca | 08-25-2011 |
| 20110201086 | METHOD FOR PRODUCING RECOMBINANT VIRUS - To provide a method for producing, at high purity, a recombinant baculovirus which exhibits intended immunogenicity and is useful for a pharmaceutical (e.g., a vaccine), a transfer vector for use in the production of the recombinant baculovirus, and a method for producing the transfer vector. The method for producing a transfer vector which includes therein a fusion gene containing at least one gene encoding a virus-particle-forming protein and a gene encoding a foreign immunogenic protein, the method including modifying the polynucleotide sequence of the gene encoding the virus-particle-forming protein so as not to alter the amino acid residues constituting a corresponding naturally occurring virus-particle-forming protein and/or modifying the polynucleotide sequence of the gene so that a portion of the amino acid residues constituting the naturally occurring virus-particle-forming protein is deleted. | 08-18-2011 |
| 20110200712 | LOW-CALORIE BEVERAGE COMPOSITION CONTAINING LUO HAN GUO EXTRACT AND SUCRALOSE - An object of the present invention is to provide a low-calorie drink composition having a refreshing sweet taste, the composition being free of bitter taste, salty taste, astringent taste or the like that inorganic electrolyte-containing drinks generally have. | 08-18-2011 |
| 20110189134 | FERMENTATION PRODUCT CONTAINING EQUOL-PRODUCING MICROORGANISM HAVING MAINTAINED EQUOL-PRODUCING ABILITY, AND METHOD FOR PRODUCING SAME - An object of the present invention is to provide a fermented product containing equol-producing microorganisms in the state of living cells by which equol production ability is maintained. | 08-04-2011 |
| 20110165249 | PHARMACEUTICAL SOLID PREPARATION - An object of the present invention is to provide a gradual disintegration-type, sustained-release pharmaceutical solid preparation whose pharmacologically active substance release behavior is controlled. The solid pharmaceutical preparation of the present invention is a matrix-type preparation containing: (a) a pharmacologically active substance; (b) calcium polycarbophil; and (c) a specific sugar and/or sugar alcohol. | 07-07-2011 |
| 20110150847 | METHOD OF THREE-DIMENSIONALLY CULTURING CHONDROCYTES - It is intended to provide a method of three-dimensionally culturing normal joint chondrocytes; the production and supply of chondrocytes; and a transplantation material to be used in an injured site in a joint tissue. | 06-23-2011 |
| 20110105718 | NEL-RELATED PROTEIN TYPE 1 ANTIBODY - The present invention provides novel human genes, for example a novel human gene comprising a nucleotide sequence coding for the amino acid sequence shown under SEQ ID NO:1. The use of the genes makes it possible to detect the expression of the same in various tissues, analyze their structures and functions, and produce the human proteins encoded by the genes by the technology of genetic engineering. Through these, it becomes possible to analyze the corresponding expression products, elucidate the pathology of diseases associated with the genes, for example hereditary diseases and cancer, and diagnose and treat such diseases. | 05-05-2011 |
| 20110067696 | POWDER INHALER - An object of the present invention is to provide a powder inhaler that does not require shaking, and that therefore can be operated in an efficient manner. | 03-24-2011 |
| 20110045491 | CYCLIC NUCLEOTIDE-SPECIFIC PHOSPHODIESTERASES FROM LEISHMANIA AND USES THEREOF - The present invention, relates to novel amino acid and nucleic acid sequences of cyclic nucleotide-specific phosphodiesterases from the parasite | 02-24-2011 |
| 20110038958 | USE OF CANNABINOIDS IN COMBINATION WITH AN ANTI-PSYCHOTIC MEDICAMENT - The present invention relates to the use of one or more cannabinoids in combination with one or more anti-psychotic medicaments for use in the prevention or treatment of psychosis and psychotic disorders. Preferably the one or more cannabinoids are taken from the group: cannabidiol (CBD); cannabidiolic acid (CBDA); tetrahydrocannbidivarin (THCV); tetrahydrocannbidivarinin acid (THCVA); cannabichromene (CBC); cannabichromenic acid (CBCA); cannabigerol (CBG) and cannabigerolic acid (CBGA). Preferably the anti-psychotic medication is an atypical anti-psychotic medication. | 02-17-2011 |
| 20110034545 | DOUBLE-STRANDED LIPID-MODIFIED RNA HAVING HIGH RNA INTERFERENCE EFFECT - An object of the present invention is to provide a novel double-stranded RNA that has high resistance to nuclease and cellular uptake efficiency and that can produce an excellent RNA interference effect. The present invention provides a double-stranded lipid-modified RNA comprising a sense strand having a nucleotide sequence complementary to a target sequence in a target gene, and an antisense strand having a nucleotide sequence complementary to the sense strand, the double-stranded RNA being capable of suppressing the expression of the target gene, and the sense strand having a double-stranded lipid bound directly or via a linker to at least one of the first to sixth nucleotides from the 5′ end. | 02-10-2011 |
| 20110033564 | EQUOL-CONTAINING EXTRACT, METHOD FOR PRODUCTION THEREOF, METHOD FOR EXTRACTION OF EQUOL, AND EQUOL-CONTAINING FOOD - The present invention relates to an extract obtained by extracting useful components containing equol from an equol-containing fermented soybean hypocotyl, and to a method for producing the same. | 02-10-2011 |
| 20110020848 | METHOD FOR DETECTION OF PNEUMOCOCCUS - To provide an immunological detection method which can detect or quantify a pneumococcal antigen in a sample derived from a living body conveniently, rapidly, and with high sensitivity, and an antibody for use in the method. The present invention provides an antibody which specifically recognizes a pneumococcal F-antigen; a method for detecting or quantitating a pneumococcal antigen, characterized in that the method detects or quantitates a pneumococcal F-antigen in a sample derived from a living body through immunological assay employing the antibody; and a kit for detecting a pneumococcal antigen, the kit containing the antibody. | 01-27-2011 |
| 20100331423 | AQUEOUS SOLUTION OF OLANEXIDINE, METHOD OF PREPARING THE AQUEOUS SOLUTION, AND DISINFECTANT - The present invention provides a disinfectant that contains olanexidine in a concentration sufficient to exhibit an effective bactericidal effect, and that has hardly any side effects such as skin irritation. Specifically, the present invention provides a disinfectant containing an aqueous solution that contains olanexidine and at least an equimolar amount of gluconic acid, and substantially contains neither an acid other than gluconic acid nor a salt of the acid other than gluconic acid. | 12-30-2010 |
| 20100331421 | DISINFECTANT AND/OR BACTERICIDAL AQUEOUS COMPOSITIONS - The present invention provides a disinfectant and/or bactericidal aqueous composition containing an olanexidine acid addition salt and and a cyclodextrin. | 12-30-2010 |
| 20100330627 | ENZYME ASSOCIATED WITH EQUOL SYNTHESIS - An object of the present invention is to provide enzymes associated with equol synthesis, genes coding such enzymes, and a process for producing equol and its intermediates using the enzymes and genes. | 12-30-2010 |
| 20100323006 | PHARMACEUTICAL SOLID PREPARATION COMPRISING BENZAZEPINES AND PRODUCTION METHOD THEREOF - The subject invention provides a novel pharmaceutical solid preparation that has superior disintegration properties and excellent solubility, leading to sufficient absorbability of active ingredients through the gastrointestinal tract. The pharmaceutical solid preparation of the present invention comprises:
| 12-23-2010 |
| 20100305190 | NUCLEIC ACID COMPLEX AND NUCLEIC ACID DELIVERY COMPOSITION - The present invention provides a nucleic acid complex with low toxicity and high safety that can persistently maintain a nucleic acid, such as siRNA or the like, in a cell; and a nucleic acid delivery composition that can efficiently deliver the nucleic acid complex into a cell. A nucleic acid complex with low toxicity and high safety that can persistently maintain a nucleic acid in a cell can be obtained by forming a complex using a nucleic acid to be introduced into a cell, and a highly branched cyclic dextrin. Moreover, when a carrier comprising (A) a diacylphosphatidylcholine, (B) cholesterol and/or a derivative thereof, and (C) an aliphatic primary amine is used as a nucleic acid delivery carrier to introduce the nucleic acid complex into a cell, the safety, the efficiency of intracellular delivery, and the persistence of the nucleic acid in the cell can be further improved. | 12-02-2010 |
| 20100298411 | LIPID-MODIFIED DOUBLE-STRANDED RNA HAVING POTENT RNA INTERFERENCE EFFECT - An object of the present invention is to provide a novel double-stranded RNA that has high nuclease resistance and high cellular uptake efficiency, and that is capable of producing an excellent RNA interference effect. The present invention provides a lipid-modified double-stranded RNA comprising a sense strand having a nucleotide sequence complementary to a target sequence, and an antisense strand having a nucleotide sequence complementary to the sense strand, the double-stranded RNA being capable of inhibiting the expression of the target gene, the sense strand having a lipid linked to at least one of the first to sixth nucleotides from the 5′ end side directly or via a linker. | 11-25-2010 |
| 20100292176 | ANTITUMOR AGENT - Provided is a sugar-cholestanol compound which can be readily synthesized, and which exhibits a satisfactory antitumor activity. | 11-18-2010 |
| 20100285499 | HUMAN p51 GENES AND GENE PRODUCTS THEREOF - Novel human genes falling within the category of family genes relating to p53 gene which is known as a cell proliferation regulatory gene, and gene products thereof. A human p51 gene characterized by containing a base sequence encoding an amino acid sequence represented by SEQ ID NO:1; a human p51 gene having a base sequence consisting of the 145- to 1488-bases in the sequence represented by SEQ ID NO:2; vectors containing these genes; host cells transformed with these vectors; a process for producing a p51 protein having the amino sequence represented by SEQ ID NO:1; which comprises culturing the above host cells and harvesting the protein from the thus obtained culture; and the p51 protein having the amino acid sequence represented by SEQ ID NO:1. | 11-11-2010 |
| 20100273176 | METHOD OF JUDGING RISK FOR ONSET OF DRUG-INDUCED GRANULOCYTOPENIA - Means for determining the presence of the risk of drug-induced granulocytopenia in a human is provided. | 10-28-2010 |
| 20100273175 | METHOD OF JUDGING RISK FOR ONSET OF DRUG-INDUCED GRANULOCYTOPENIA - Means for determining the presence of the risk of drug-induced granulocytopenia in a human is provided. | 10-28-2010 |
| 20100261880 | LY6H POLYPEPTIDE - The invention provides a brain-specific gene useful in treating Alzheimer's disease, for instance, which comprises a nucleotide sequence cording for the amino acid sequence shown in SQ ID NO:1 and fragments thereof; an expression vector comprising the gene; a host cell comprising the expression vector; an expression product of the gene; an antibody against the product; a therapeutic and prophylactic composition for neurodegenerative disease; and the like. | 10-14-2010 |
| 20100261720 | HETEROCYCLIC COMPOUND AND PHARMACEUTICAL COMPOSITION THEREOF - The present invention provides a heterocyclic compound represented by General Formula (1): | 10-14-2010 |
| 20100249104 | METHODS FOR USING VASOPRESSIN ANTAGONISTS WITH ANTHRACYCLINE CHEMOTHERAPY AGENTS TO REDUCE CARDIOTOXICITY AND/OR IMPROVE SURVIVAL - The present invention relates to methods of reducing cardiotoxicity and/or improving survival from treatment with anthracycline agents comprising administering a therapeutically effective amount of a composition comprising a vasopressin antagonist compound or a pharmaceutically acceptable salt thereof as an active ingredient, administered simultaneously or prior to the anthracycline administration. | 09-30-2010 |
| 20100210661 | STAT3/5 ACTIVATION INHIBITOR - An object of the present invention is to provide a STAT3/5 activation inhibitor. The present invention provides a STAT3/5 activation inhibitor containing an aromatic compound represented by the general formula or a salt thereof as an active ingredient: | 08-19-2010 |
| 20100203151 | MICROSPHERES HAVING CORE/SHELL STRUCTURE - Disclosed are microspheres having a core/shell structure and a spherical shape, wherein (a) the core comprises solid-state aripiprazole, and (b) the shell coats all or most of the surface of the core, and the shell comprises a biodegradable polymer; a process for producing the microspheres; and an injectable aqueous suspension formulation containing the microspheres; and the like. | 08-12-2010 |
| 20100192946 | METERED DOSE INHALER - The present invention provides an improved metered dose inhaler utilizing the property of the aerosol canister. The metered dose inhaler includes: a housing body ( | 08-05-2010 |
| 20100167321 | EPITOPE/PEPTIDE RECOGNIZED BY HLA-A2402-RESTRICTED EP-CAM-SPECIFIC CTL AND USE OF THE SAME - A peptide consisting essentially of the amino acid sequence represented by SEQ ID NO:1; a peptide consisting essentially of the amino acid sequence represented by SEQ ID NO:2; or a mutant peptide consisting essentially of an amino acid sequence derived from the amino acid sequence represented by SEQ ID NO:1 or 2 by addition, deletion or substitution of one or more amino acids, the peptide being capable of forming a complex with an HLA-A2402 molecule to be recognized by HLA-A2402-restricted cytotoxic T lymphocytes or induce such lymphocytes. Such a peptide is useful as a cancer vaccine for epithelial cancer patients having HLA-A2402. | 07-01-2010 |
| 20100160611 | HUMAN SKELETAL MUSCLE-SPECIFIC UBIQUITIN-CONJUGATING ENZYME - The present invention provides novel human genes, for example a novel human gene comprising a nucleotide sequence coding for the amino acid sequence shown under SEQ ID NO:1. The use of the genes makes it possible to detect the expression of the same in various tissues, analyze their structures and functions, and produce the human proteins encoded by the genes by the technology of genetic engineering. Through these, it becomes possible to analyze the corresponding expression products, elucidate the pathology of diseases associated with the genes, for example hereditary diseases and cancer, and diagnose and treat such diseases. | 06-24-2010 |
| 20100159072 | Fermented Tea Beverage and Tea Beverage - The present invention provides a tea-based fermentation beverage comprising a tea-based fermentation liquid with at least one species of lactic acid bacteria selected from the group consisting of | 06-24-2010 |
| 20100137407 | SINGLE-CHAIN CIRCULAR RNA AND METHOD OF PRODUCING THE SAME - The present invention relates to a single-chain circular RNA having a sustained or slow-releasing RNA interference effect, characterized in that the single-chain circular RNA comprises a sense strand sequence, an antisense strand sequence complementary to the sense strand sequence, identical or different two loop sequences between the sense strand and the antisense strand, connecting both strands, wherein the sense strand and the antisense strand are paired to form a stem. | 06-03-2010 |
| 20100130546 | QUINOLONE COMPOUND AND PHARMACEUTICAL COMPOSITION - The present invention provides a quinolone compound represented by General Formula (1) | 05-27-2010 |
| 20100130508 | PHARMACEUTICAL COMPOSITION COMPRISING 2,3-DIHYDRO-6-NITROIMIDAZO [2,1-B] OXAZOLE DERIVATIVES - A pharmaceutical composition according to the present invention comprises: (I) at least one member selected from the group consisting of oxazole compounds, optically active isomers thereof, and salts thereof, the oxazole compounds being represented by general formula (1): wherein R | 05-27-2010 |
| 20100104595 | LYOPHILIZED PREPARATION COMPRISING INFLUENZA VACCINE, AND METHOD FOR PREPARATION THEREOF - The present invention aims to provide a freeze-dried preparation in which the influenza vaccine exhibits improved stability. | 04-29-2010 |
| 20100063131 | PROMPT NUCLEIC ACID DELIVERY CARRIER COMPOSITION - An object of the present invention is to provide a carrier composition for nucleic acid delivery, which can efficiently deliver a nucleic acid into cells when a nucleic acid such as siRNA is administered to animal-derived cells or animals, and also has low toxicity and high safety, and a composition for nucleic acid delivery containing the carrier composition and nucleic acid. | 03-11-2010 |
| 20100062053 | CHOLESTANOL DERIVATIVE FOR COMBINED USE - The invention provides a cancer chemotherapeutic agent which has fewer side effects and excellent efficacy. The cancer chemotherapeutic agent of the invention includes a cholestanol derivative represented by formula (1): | 03-11-2010 |
| 20100048878 | HUMAN GENE - The present invention provides novel human genes, for example a novel human gene comprising a nucleotide sequence coding for the amino acid sequence shown under SEQ ID NO:1. The use of the genes makes it possible to detect the expression of the same in various tissues, analyze their structures and functions, and produce the human proteins encoded by the genes by the technology of genetic engineering. Through these, it becomes possible to analyze the corresponding expression products, elucidate the pathology of diseases associated with the genes, for example hereditary diseases and cancer, and diagnose and treat such diseases. | 02-25-2010 |
| 20090311353 | EQUAL-CONTAINING FERMENTATION PRODUCT OF SOYBEAN EMBRYONIC AXIS, AND METHOD FOR PRODUCTION THEREOF - An object of the invention is to provide an equol-containing fermented soybean hypocotyl material that is useful for foods, pharmaceutical preparations, cosmetic products, etc. | 12-17-2009 |
| 20090258923 | Carrier Composition for Nucleic Acid Transport - An object of the present invention is to provide a nucleic acid delivery carrier composition of low toxicity and high safety, the carrier composition, when used to administer a nucleic acid such as an siRNA into an animal-derived cell or organism, being capable of delivering efficiently the nucleic acids into the cells while protecting it from being degraded; and a nucleic acid deliver composition containing the carrier and a nucleic acid. | 10-15-2009 |
| 20090221586 | OXAZOLE COMPOUND AND PHARMACEUTICAL COMPOSITION - The present invention provides a oxazole compound represented by Formula (1), or a salt thereof: | 09-03-2009 |
| 20090205656 | POWDER INHALER - The subject invention provides a powder inhaler enabling the user to complete powder drug inhalation with fewer steps, for improved user convenience. | 08-20-2009 |
| 20090162291 | MAGNETIC RESONANCE CONTRAST MEDIUM USING POLYETHYLENE GLYCOL AND MAGNETIC RESONANCE IMAGE PICK-UP METHOD - An object of the invention is to provide a technique that is safe and quantitative, and is capable of continuously acquiring a magnetic resonance image with a short repetition time. | 06-25-2009 |
| 20090142783 | Human p51 Genes and Gene Products Thereof - Novel human genes falling within the category of family genes relating to p53 gene which is known as a cell proliferation regulatory gene, and gene products thereof. A human p51 gene characterized by containing a base sequence encoding an amino acid sequence represented by SEQ ID NO:1; a human p51 gene having a base sequence consisting of the 145- to 1488-bases in the sequence represented by SEQ ID NO:2; vectors containing these genes; host cells transformed with these vectors; a process for producing a p51 protein having the amino sequence represented by SEQ ID NO:1; which comprises culturing the above host cells and harvesting the protein from the thus obtained culture; and the p51 protein having the amino acid sequence represented by SEQ ID NO:1. | 06-04-2009 |
| 20090082575 | PROCESS FOR PRODUCTION OF 2-CHLORO-4-NITROIMIDAZOLE - The present invention provides a process for production of 2-chloro-4-nitroimidazole in a high yield and at a high purity by a simple operation in a safer manner involving a low risk of explosion or the like. The present invention provides a process for production of 2-chloro-4-nitroimidazole represented by the formula (1): comprising a reaction of a 1-alkoxyalkyl-2-bromo-4-nitroimidazole compound represented by the general formula (7): wherein R1 represents a lower alkyl group, and n represents an integer of 1 to 3, with hydrogen chloride. | 03-26-2009 |
| 20090081790 | Polynucleotide for Target Gene - The present invention provides a single strand polynucleotide sequence comprising a target gene, a complementary strand nucleic acid sequence, and a component sequence. | 03-26-2009 |
| 20090048350 | GASTROINTESTINAL ABSORPTION ENHANCER MEDIATED BY PROTON-COUPLED TRANSPORTER AND ITS PREPARING METHOD - The present invention provides a pharmaceutical preparation that can improve absorption of a pharmaceutical compound in the gastrointestinal tract and that provides, through oral administration or like method, a blood concentration from which sufficient remedial effects can be expected, and a method for producing such a preparation. The invention is directed to a pharmaceutical preparation exhibiting excellent gastrointestinal absorbability comprising a compound recognized by a proton-coupled transporter and a pH-sensitive polymer in an amount sufficient for the gastrointestinal tract to acquire a pH at which the proton-coupled transporter optimally absorbs the compound into a cell. | 02-19-2009 |
| 20090047357 | METHOD OF PRODUCING DRUG-CONTAINING WAX MATRIX PARTICLES, EXTRUDER TO BE USED IN THE METHOD AND SUSTAINED-RELEASE PREPARATION CONTAINING CILOSTAZOL - The present invention aims to provide a method for producing, by a simple method, drug-containing wax matrix granules, particularly drug-containing wax matrix granules having an average particle diameter of 1 mm or lower, while avoiding liquid blockage due to the recrystallization of a molten drug during the period from a melting step to a spray step. | 02-19-2009 |
| 20080275218 | LY6H GENE - The invention provides a brain-specific gene useful in treating Alzheimer's disease, for instance, which comprises a nucleotide sequence cording for the amino acid sequence shown in SEQ ID NO:1 and fragments thereof; an expression vector comprising the gene; a host cell comprising the expression vector; an expression product of the gene; an antibody against the product; a therapeutic and prophylactic composition for neurodegenerative disease; and the like. | 11-06-2008 |
| 20080268489 | Calcium Ion Leakage Inhibitors - A polypeptide exhibiting the effect of inhibiting Ca | 10-30-2008 |
| 20080260878 | Composition for Prevention or Alleviation of Pigmentation - A composition for the prevention or alleviation of pigmentation which can produce the higher effect of preventing or alleviating pigmentation. The composition for the prevention or alleviation of pigmentation comprises a combination of (A) at least one member selected from the group consisting of adenosine 5′-monophosphate and salts thereof with (B) at least one member selected from the group consisting of arbutin, ellagic acid, 4-alkylresorcinols, linoleic acid, tranexamic acid, salts of these, Chamomilla recuita extract, and Ubiquinone. | 10-23-2008 |
| 20080221084 | METHOD FOR REDUCING INFARCTION USING VASOPRESSIN ANTAGONIST COMPOUNDS, AND COMPOSITIONS AND COMBINATIONS THEREFOR - The present invention relates to a method for reducing infarction comprising administering to a patient ion need thereof a therapeutically effective amount of a composition comprising as an active ingredient a vasopressin antagonist compound and to a composition useful therefor. The present invention also relates to a method for reducing infarction comprising administering to a patient in need thereof a therapeutically effective amount of a combination of a vasopressin antagonist compound and a beta-blocker and to combinations useful therefor. The methods, compositions and combinations of the present invention can be used for reducing infarction in the heart (myocardial infarction) and the brain (stroke). The methods, compositions and combinations of the present invention can also be used for the treatment and/or prevention of hypertension, edema, ascites, heart failure, renal function disorder, vasopressin inappropriate secretion syndrome (SIADH), hepatocirrhosis, hyponatremia, hypokalemia, polycystic kidney disease, diabetes, or circulation disorder. | 09-11-2008 |
| 20080199859 | Identification Marker Responsive to Interferon Therapy for Renal Cell Cancer - The present invention provides an identification marker responsive to IFN therapy for renal cell cancer and a means of detecting the same. Namely, a method which comprises preparing a genomic DNA of a human gene or a complementary strand thereof from a specimen of a patient with renal cell cancer, analyzing the DNA sequence of the genomic DNA or the complementary strand thereof to determine the gene polymorphism of the human gene, and evaluating the tumor-suppression effect of IFN therapy on renal cell cancer by using the polymorphism as an indicator. | 08-21-2008 |
